Royal Bank Of Canada Issues Pessimistic Forecast for Abbott Laboratories (NYSE:ABT) Stock Price

Abbott Laboratories (NYSE:ABT) had its price objective dropped by equities research analysts at Royal Bank Of Canada from $135.00 to $130.00 in a report released on Friday, Marketbeat reports. The brokerage presently has an “outperform” rating on the healthcare product maker’s stock. Royal Bank Of Canada’s price target would suggest a potential upside of 34.17% from the company’s current price.

A number of other brokerages have also commented on ABT. Stifel Nicolaus decreased their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday. Weiss Ratings lowered Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Benchmark decreased their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday. Piper Sandler decreased their price objective on Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating for the company in a report on Friday. Finally, Wells Fargo & Company decreased their price objective on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $121.00.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $96.89 on Friday. Abbott Laboratories has a one year low of $93.92 and a one year high of $139.06. The firm has a market capitalization of $168.75 billion, a price-to-earnings ratio of 27.14, a PEG ratio of 1.57 and a beta of 0.79. The business has a 50-day simple moving average of $107.89 and a 200 day simple moving average of $118.65. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.The business had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same period in the previous year, the company posted $1.09 EPS. The firm’s revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the transaction, the executive vice president owned 146,377 shares in the company, valued at $16,918,253.66. The trade was a 0.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the transaction, the executive vice president owned 104,291 shares in the company, valued at $12,053,953.78. The trade was a 0.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 3,055 shares of company stock worth $353,097. Company insiders own 0.46% of the company’s stock.

Hedge Funds Weigh In On Abbott Laboratories

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Gemmer Asset Management LLC boosted its stake in shares of Abbott Laboratories by 2.9% in the 3rd quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock worth $368,000 after buying an additional 78 shares during the last quarter. Global Financial Private Client LLC boosted its stake in shares of Abbott Laboratories by 3.3% in the 3rd quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock worth $331,000 after buying an additional 79 shares during the last quarter. Citizens & Northern Corp boosted its stake in shares of Abbott Laboratories by 0.4% in the 3rd quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock worth $2,930,000 after buying an additional 79 shares during the last quarter. American National Bank of Texas boosted its stake in shares of Abbott Laboratories by 2.4% in the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock worth $427,000 after buying an additional 79 shares during the last quarter. Finally, Nia Impact Advisors LLC boosted its stake in shares of Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after buying an additional 79 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Preliminary settlement reached in six shareholder derivative suits tied to Abbott’s U.S. infant‑formula business, reducing litigation overhang for investors. Read More.
• Positive Sentiment: New data on Cancerguard MCED (multi‑cancer early detection) presented at AACR 2026 — important for Abbott’s growth thesis since the Exact Sciences deal expanded its oncology diagnostics exposure. Continued clinical progress supports longer‑term revenue upside. Read More.
• Positive Sentiment: Insiders added roughly $3.1M of stock, and a number of analysts still see upside — some calling the post‑acquisition pullback a buying opportunity given valuation and Abbott’s dividend track record. Read More. Read More.
• Neutral Sentiment: Q1 results: adjusted EPS $1.15 (vs. $1.14 est.) and revenue $11.16B (vs. $10.99B); company set FY 2026 adjusted EPS guidance to $5.38–$5.58 and Q2 guide to $1.25–$1.31, explicitly including ~$0.20 of dilution from the Exact Sciences acquisition. Investors are parsing beat vs. the guidance change. Read More.
• Neutral Sentiment: Earnings call transcript and analyst commentary emphasize medical‑device strength offset by Diagnostics/Nutrition softness and acquisition-related margin pressure — useful for active traders but mixed for near‑term stock direction. Read More.
• Negative Sentiment: Market reaction: shares fell after the print because Abbott trimmed guidance and flagged Nutrition weakness and margin compression; coverage shows the takeover (≈$21–23B) is dilutive near term. Read More.
• Negative Sentiment: Many brokers lowered price targets and some cut forecasts following Q1/guidance — several firms kept positive ratings but reduced targets (examples include RBC, Jefferies, Raymond James, Citi and others), amplifying short‑term selling pressure. Read More.
• Negative Sentiment: Analyst notes and headlines highlighted the EPS guidance cut and Nutrition slump as primary reasons for the earlier drop — these remain catalysts to watch for the next quarter. Read More.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.